The biopharma industry entered 2026 with renewed momentum in dealmaking. But venture capital (VC) investors maintained their cautious stance on early-stage innovation. JPMorgan’s Q1 2026 Biopharma Licensing and Venture Report showed selective strength across licensing and M&A activity. Meanwhile, venture funding patterns revealed a widening gap between early and late-stage capital allocation.

Biopharma licensing partnerships reached $82.7 billion in announced value during Q1 2026, underscoring the industry’s continued appetite for external innovation. However, the deal structures tell a more nuanced story: upfront cash represented just 6% of total deal value, signaling that risk is being firmly pushed into milestone-based back-end payments.

This shift reflects a market that remains open but increasingly risk averse. Large-cap biopharma companies are actively pursuing external innovation through licensing and acquisitions, but they’re doing so with tightly controlled upfront economics and milestone-heavy structures that transfer development risk to partners. For the most competitive assets upfront economics remained strong. This suggests that quality assets with strong validation continue to command premium terms.

Related:JPM 2025: Gilead inks inflammatory deal with LEO

M&A activity maintains momentum 

Biopharma M&A totaled $40.9 billion across 32 deals in Q1 2026. The report detailed how strategic buyers remained focused on pipeline replenishment and selective late-stage acquisitions, with private companies continuing to account for a significant share of target volume.

Notable transactions during the quarter included Merck’s $6.7 billion acquisition of Terns Pharmaceuticals and Eli Lilly’s $7.8 billion acquisition of Centessa Pharmaceuticals ($6.3 billion upfront). These deals exemplify the industry’s focus on de-risked, later-stage assets with credible paths to commercialization.

The VC landscape presented a more challenging picture. Biopharma venture funding totaled $6.9 billion in Q1 2026, down from $8.6 billion in Q1 2025, with deal count also trending lower. The data reveals a concerning pattern: seed and Series A financing continues drifting back toward post-pandemic lows. 

The gap between early-stage and late-stage capital is widening once again, as investors and acquirers double down on later-stage, de-risked assets with credible routes to licensing, M&A, or initial public offering (IPO). This disciplined approach to capital deployment reflects a market that won’t subsidize uncertainty, placing increased pressure on early-stage biotechs to demonstrate strong science, robust data, and defensible IP positions.

Related:JPM 2025: J&J snaps up neuroscience biotech Intra-Cellular for $14.6bn

What this means for the biotech ecosystem

The Q1 2026 data paints a picture of an industry in transition. While licensing is effectively carrying the ecosystem and providing crucial capital for innovation, the structures matter significantly. Big headline values can mask the reality of tightly controlled upfronts and milestone-dependent economics.

For early-stage biotechs, the message is clear: the market demands excellence. Companies must demonstrate not just promising science, but also strong data packages, defensible intellectual property, and clear pathways to value-creating exits. 

For large-cap biopharma, the strategy appears to be working. By maintaining active business development efforts while carefully managing risk through deal structures, these companies are accessing external innovation without overextending their balance sheets. The challenge will be ensuring that this risk-averse approach doesn’t inadvertently stifle the early-stage innovation that feeds the industry’s long-term pipeline.

As the year progresses, the sustainability of this model will be tested. If early-stage funding continues to contract, the pipeline of innovative assets available for licensing and acquisition in future years may begin to thin. 

Related:JPM 2025: GSK shells out $1.15bn to buy oncology firm IDRx